Hypoxic-Ischemic Encephalopathy Clinical Trial
— PAEANOfficial title:
Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy With Erythropoietin: A Phase III Randomised Placebo Controlled Multicentre Clinical Trial
Verified date | June 2024 |
Source | University of Sydney |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy (HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared to hypothermia alone.
Status | Completed |
Enrollment | 313 |
Est. completion date | April 30, 2024 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 23 Hours |
Eligibility | Inclusion Criteria: - Male or female infants born greater than or equal to 35+0 weeks gestation and able to be randomised less than 23 hours after birth - One or more of the following indicators of perinatal depression: 1. Apgar less than or equal to 5 at 10 minutes after birth, OR 2. Receiving ongoing resuscitation e.g. assisted ventilation (positive pressure ventilation or CPAP) or chest compressions at 10 minutes after birth, OR 3. on cord blood or arterial or venous blood obtained at less than 60 minutes after birth, either pH less than 7.00 OR base deficit greater than or equal to 12.0 mmol/L - Moderate to severe encephalopathy, defined between one and six hours after birth by one or both of the following: 1. 3 out of 6 modified Sarnat criteria indicating moderate/severe encephalopathy, OR 2. 2 out of 6 modified Sarnat criteria plus seizure(s) requiring anticonvulsant treatment (diagnosed either clinically or using EEG monitoring) at any time prior to randomisation - Hypothermia treatment initiated by 6 hours ofa ge; i.e. controlled whole-body cooling planned to continue for 72 hours to a target temperature (adjusted manually or with a device) and subsequent controlled re-warming - Study treatment planned to start within 24 hours after birth (as soon as feasible after randomisation) - At least one parent greater than or equal to 18 years of age - Anticipated ability to collect primary endpoint at 2 years of age - Signed, written informed parental consent Exclusion Criteria: - Contraindications to investigational product - Indication prior to randomisation for erythropoietin or any other erythropoietic stimulating agent to be given during the first two weeks of life - Severe intrauterine growth restriction (birth weight less than 1800g) - Suspected major chromosomal or congenital anomalies - Head circumference less than 3rd centile below the mean for gestation and gender - Infant for whom imminent withdrawal of care is being planned |
Country | Name | City | State |
---|---|---|---|
Australia | Flinders Medical Centre | Bedford Park | South Australia |
Australia | Royal Prince Alfred Hospital | Camperdown | New South Wales |
Australia | Monash Medical Centre | Clayton | Victoria |
Australia | Canberra Hospital | Garran | Australian Capital Territory |
Australia | Mercy Hospital for Women | Heidelberg | Victoria |
Australia | Royal Women's & Brisbane Hospital | Herston | Queensland |
Australia | Royal Hobart Hospital | Hobart | Tasmania |
Australia | Nepean Hospital | Kingswood | New South Wales |
Australia | John Hunter Hospital | New Lambton | New South Wales |
Australia | Women's and Children's Hospital | North Adelaide | South Australia |
Australia | The Royal Children's Hospital | Parkville | Victoria |
Australia | The Royal Women's Hospital | Parkville | Victoria |
Australia | Royal Hospital for Women | Randwick | New South Wales |
Australia | Mater Mothers' Hospital | South Brisbane | Queensland |
Australia | Royal North Shore Hospital | St Leonards | New South Wales |
Australia | King Edward Memorial Hospital | Subiaco | Western Australia |
Australia | Princess Margaret Hospital | Subiaco | Western Australia |
Australia | Westmead Hospital | Westmead | New South Wales |
New Zealand | Auckland City Hospital | Auckland | |
New Zealand | Middlemore Hospital | Auckland | |
New Zealand | Christchurch Hospital | Christchurch | |
New Zealand | Waikato Hospital | Hamilton | |
New Zealand | Wellington Hospital | Wellington | |
Singapore | KK Women's and Children's Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
University of Sydney | National Health and Medical Research Council, Australia |
Australia, New Zealand, Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Distribution of overall disability | Distribution of overall severity across 4 domains: 1) normal, 2) mild motor or cognitive deficit, 3) moderate/severe motor or cognitive deficit, and 4) death | 2 years of age | |
Primary | Composite measure of death or moderate/severe disability | Moderate/severe disability is defined as any cerebral palsy and a Gross Motor Function Classification Scale (GMFCS) score greater than or equal to 1), or Bayley Scale of Infant Development III (BSDIII) less than or equal to 80 | 2 years of age | |
Secondary | Death | Death from any cause | Any time from Day 1 of treatment to 2 years of age | |
Secondary | Cerebral palsy (CP), assessed by paediatric assessment | Any incidence of CP (any of quadriplegia, triplegia, hemiplegia, diplegia or monoplegia) | 2 years of age | |
Secondary | Moderate/severe motor deficit | Composite of any incidence of CP (any of quadriparesis, CP, hemiparesis or diparesis) AND any level of functional impairment using the GMFCS greater than or equal to 1.0 | 2 years of age | |
Secondary | Moderate/severe cognitive deficit | Defined as a BSDIII cognitive score less than or equal to 80 | 2 years of age | |
Secondary | Need for supplemental respiratory support (includes tracheostomy, ventilator, high flow nasal cannula, CPAP or oxygen dependency) | Supplemental respiratory support includes tracheostomy, ventilator, high flow nasal cannula, CPAP or oxygen dependency | 2 years of age | |
Secondary | Need for nutritional support (includes gastrostomy or nasogastric feeds) | Nutritional support includes gastrostomy or nasogastric feeds | 2 years of age | |
Secondary | Major cortical visual impairment by paediatric examination | Impairment as assessed by paediatric assessment | 2 years of age | |
Secondary | Hearing impairment status by paediatric examination - requirement for hearing aids | Defined as the requirement for hearing aids (either diagnosis of: Hears well or with only a little difficulty WITH a hearing aid OR Has severe hearing difficulty even with a hearing aid or hearing is not helped with an aid) | 2 years of age | |
Secondary | Epilepsy (history of 2 or more afebrile unprovoked seizures since discharge from neonatal unit where PAEAN study treatment was provided, or use of anticonvulsants at 2 years of age). | Defined by history of 2 or more afebrile unprovoked seizures since discharge from neonatal unit where PAEAN study treatment was provided, or use of anticonvulsants at 2 years of age | 2 years of age | |
Secondary | Cost of healthcare and service utilisation | Defined as a composite of parent completed questionnaire data and Medicare service use | 2 years of age | |
Secondary | Frequency of selected adverse events (AEs) of interest, including deaths | Frequency of selected adverse events (AEs) of interest up to 30 days after the last study dose | Up to 30 days post study treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05048550 -
Babies in Glasses; a Feasibility Study.
|
N/A | |
Recruiting |
NCT05514340 -
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
|
Phase 2 | |
Recruiting |
NCT05836610 -
Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates
|
Phase 4 | |
Completed |
NCT03024021 -
Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
|
||
Completed |
NCT01913340 -
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT02260271 -
Florida Neonatal Neurologic Network
|
||
Terminated |
NCT01192776 -
Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)
|
N/A | |
Completed |
NCT06344286 -
The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE
|
N/A | |
Recruiting |
NCT05901688 -
Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
|
||
Recruiting |
NCT02894866 -
Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy
|
N/A | |
Recruiting |
NCT03682042 -
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up
|
N/A | |
Recruiting |
NCT03657394 -
Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries
|
N/A | |
Withdrawn |
NCT03681314 -
Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU)
|
N/A | |
Completed |
NCT03485781 -
Propofol-induced EEG Changes in Hypoxic Brain Injury
|
||
Not yet recruiting |
NCT06429007 -
A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury
|
Phase 2 | |
Recruiting |
NCT05568264 -
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
|
N/A | |
Not yet recruiting |
NCT06448780 -
Dose Optimization of Caffeine for HIE
|
Phase 1 | |
Completed |
NCT02264808 -
Developmental Outcomes
|
||
Completed |
NCT05687708 -
Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia
|
N/A | |
Recruiting |
NCT06195345 -
Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)
|